Frederik Teicher Kirk

Frederik Teicher Kirk

Auto-generated profile, based on publicly available information

Frederik Teicher Kirk

Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2023 in Journal of Hepatology
Verified
Journal Article
Open access
FKFrederik Teicher Kirk
Frederik Teicher Kirk
DMDitte Emilie Munk
Ditte Emilie Munk
ESEugene Scott Swenson
Eugene Scott Swenson
AQAdam Michael Quicquaro
Adam Michael Quicquaro
MVMikkel Holm Vendelbo
Mikkel Holm Vendelbo
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl
In Wilson Disease (WD), copper accumulates in the liver and brain causing disease. Bis-choline tetrathiomolybdate (TTM) is a potent copper chelator that may have a lower risk of inducing paradoxical neurological worsening than conventional therapy for neurologic WD. To better understand the mode of action of TTM, we investigated the effects of TTM on copper absorption and biliary excretion. In a double-blind randomized setting, hepatic 64Cu activity after orally administered 64Cu was examined by PET/CT in 16 healthy volunteers before and after 7 days of TTM treatment (15 mg/d) or placebo. Oral 64Cu was administered 1 h after final TTM dose. Changes in hepatic 64Cu activity reflected changes in intestinal 64Cu uptake. Additionally, in four WD patients, distribution of 64Cu in venous blood, liver, gallbladder, kidney, and brain were followed after i.v. 64Cu dosing for up to 68 hours before and after seven days of TTM (15 mg/d), using PET/MRI. Increased gallbladder 64Cu activity was taken as evidence of increased biliary 64Cu excretion. In healthy subjects TTM reduced intestinal 64Cu uptake by 82% 15 hours after the oral 64Cu dose. In WD patients, gallbladder 64Cu activity was negligible before and after TTM, while TTM effectively retained 64Cu in the blood, significantly reduced hepatic 64Cu activity at all time points and significantly reduced cerebral 64Cu activity 2 h after the intravenous 64Cu dose. While we did not show an increase in biliary excretion of 64Cu following TTM administration, we demonstrated that TTM effectively inhibited most intestinal 64Cu uptake and retained 64Cu in the blood stream, limiting 64Cu exposure to organs like the liver and the brain. Bis-choline tetrathiomolybdate (TTM) is an investigational copper chelator for treatment of Wilson Disease. In animal studies of Wilson Disease models, TTM has been shown to facilitate biliary copper excretion. In the present human study, TTM surprisingly did not facilitate biliary copper excretion but instead reduced intestinal copper uptake to a clinically significant degree. Our study improves the understanding of human copper metabolism and the mechanism of action of TTM. Data is presented from two clinical trials:Absorption study: EudraCT 2020-005832-31Excretion study: EudraCT 2021-000102-25.

13 December 2023 in Hepatology
Verified
Journal Article
Open access
FKFrederik Teicher Kirk
Frederik Teicher Kirk
DMDitte Emilie Munk
Ditte Emilie Munk
ESEugene Scott Swenson
Eugene Scott Swenson
AQAdam Michael Quicquaro
Adam Michael Quicquaro
MVMikkel Holm Vendelbo
Mikkel Holm Vendelbo
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl
Background and Aims: Trientine (TRI) and D-penicillamine (PEN) are used to treat copper overload in Wilson disease. Their main mode of action is thought to be through the facilitation of urinary copper excretion. In a recent study, TRI was noninferior to PEN despite lower 24-hour urinary copper excretion than PEN. We tested whether TRI and/or PEN also inhibit intestinal copper absorption. Approach and Results: Sixteen healthy volunteers were examined with positron emission tomography (PET)/CT 1 and 15 hours after an oral Copper-64 (64Cu) dose. They then received 7 days of either PEN or TRI (trientine tetrahydrochloride), after which the 64Cu PET/CT scans were repeated. Venous blood samples were also collected. Pretreatment to posttreatment changes of the hepatic 64Cu uptake reflect the effect of drugs on intestinal absorption. 64Cu activity was normalized to dose and body weight and expressed as the mean standard uptake value. TRI (n=8) reduced hepatic 64Cu activity 1 hour after 64Cu dose from 6.17 (4.73) to 1.47 (2.97) standard uptake value, p<0.02, and after 15 hours from 14.24 (3.09) to 6.19 (3.43), p<0.02, indicating strong inhibition of intestinal 64Cu absorption. PEN (n=8) slightly reduced hepatic standard uptake value at 15 hours, from 16.30 (5.63) to 12.17 (1.44), p<0.04. Conclusions: In this mechanistic study, we show that TRI inhibits intestinal copper absorption, in addition to its cupriuretic effect. In contrast, PEN has modest effects on the intestinal copper absorption. This may explain why TRI and PEN are equally effective although urinary copper excretion is lower with TRI. The study questions whether the same therapeutic targets for 24-hour urinary excretion apply to both drugs.

8 April 2025 in Liver International
Verified
Journal Article
Open access
CLCamilla Lorenzen
Camilla Lorenzen
KDKaren Dons
Karen Dons
CGClàudia García‐Solà
Clàudia García‐Solà
XFXavier Forns
Xavier Forns
FKFrederik Teicher Kirk
Frederik Teicher Kirk
ZMZoe Mariño
Zoe Mariño
Background and Aims: Diagnosing Wilson disease (WD) remains challenging. The exchangeable copper (CuEXC) methodology measures the non‐ceruloplasmin‐bound copper fraction in serum. Relative exchangeable copper (REC), the ratio of CuEXC to total serum copper (Total Cu), has been proposed as a potential diagnostic biomarker. This study aimed to evaluate the diagnostic performance of these three copper biomarkers in WD.Methods: CuEXC and Total Cu levels were measured in newly diagnosed treatment‐naïve patients with WD (n = 13), treated WD (n = 91), non‐Wilsonian hepatic disease (n = 206) and non‐Wilsonian acute liver failure (n = 22). REC, CuEXC and Total Cu were compared among groups. Receiver‐operating characteristic analyses were performed.Results: Median REC was significantly elevated among patients with WD compared to all other groups combined (23.6% vs. 4.9%, p < 0.001). The opposite was found for Total Cu (3.5 μmol/L vs. 17.2 μmol/L, p < 0.001). In newly diagnosed patients with WD, median REC was significantly higher than in treated patients (29.1% vs. 21.6%, p = 0.008). The optimal diagnostic cut‐off value for REC was ≥ 13.8% (sensitivity 100% and specificity 99.6%) for newly diagnosed patients versus those with non‐Wilsonian hepatic disease. For Total Cu, the optimal cut‐off was ≤ 7.1 μmol/L (sensitivity 61.5% and specificity 99.1%) for newly diagnosed patients with WD versus those with non‐Wilsonian hepatic disease.Conclusion: Our data support the diagnostic value of REC in WD. The more broadly available Total Cu also demonstrates a strong diagnostic performance and may be useful in initial work‐up. We suggest including REC and/or Total Cu in a future revision of the Leipzig score.

25 September 2023 in JHEP Reports
Verified
Journal Article
Open access
DMDitte Emilie Munk
Ditte Emilie Munk
MVMikkel Holm Vendelbo
Mikkel Holm Vendelbo
FKFrederik Teicher Kirk
Frederik Teicher Kirk
KRKarina Stubkjær Rewitz
Karina Stubkjær Rewitz
DBDirk Andreas Bender
Dirk Andreas Bender
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl
In Wilson disease (WD), copper accumulation and increased non-ceruloplasmin-bound copper in plasma lead to liver and brain pathology. To better understand the fate of non-ceruloplasmin-bound copper, we used PET/CT to examine the whole-body distribution of intravenously injected 64-copper (64Cu). Eight patients with WD, five heterozygotes, and nine healthy controls were examined by dynamic PET/CT for 90 min and static PET/CT up to 20 h after injection. We measured 64Cu activity in blood and tissue and quantified the kinetics by compartmental analysis. Initially, a large fraction of injected 64Cu was distributed to extrahepatic tissues, especially skeletal muscle. Thus, across groups, extrahepatic tissues accounted for 45-58% of the injected dose (%ID) after 10 min, and 45-55% after 1 h. Kinetic analysis showed rapid exchange of 64Cu between blood and muscle as well as adipose tissue, with 64Cu retention in a secondary compartment, possibly mitochondria. This way, muscle and adipose tissue may protect the brain from spikes in non-ceruloplasmin-bound copper. Tiny amounts of cerebral 64Cu were detected (0.2%ID after 90 min and 0.3%ID after 6 h), suggesting tight control of cerebral copper in accordance with a cerebral clearance that is 2-3-fold lower than in muscle. Compared to controls, patients with WD accumulated more hepatic copper 6-20 h after injection, and also renal copper at 6 h. Non-ceruloplasmin-bound copper is initially distributed into a number of tissues before being redistributed slowly to the eliminating organ, the liver. Cerebral uptake of copper is extremely slow and likely highly regulated. Our findings provide new insights into the mechanisms of copper control. Maintaining non-ceruloplasmin-bound copper within the normal range is an important treatment goal in WD as this “free” copper is considered toxic to the liver and brain. We found that intravenously injected non-ceruloplasmin-bound copper quickly distributed to a number of tissues, especially skeletal muscle, subcutaneous fat, and the liver, while uptake into the brain was slow. This study offers new insights into the mechanisms of copper control, which may encourage further research into potential new treatment targets. 2016–001975-59.

3 August 2021 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
FKFrederik Teicher Kirk
Frederik Teicher Kirk
DMDitte Emilie Munk
Ditte Emilie Munk
TLTea Lund Laursen
Tea Lund Laursen
HVHendrik Vilstrup
Hendrik Vilstrup
POPeter Ott
Peter Ott
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl

1 September 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
FKFrederik Teicher Kirk
Frederik Teicher Kirk
DMDitte Emilie Munk
Ditte Emilie Munk
JEJakob Ek
Jakob Ek
LMLisbeth Birk Møller
Lisbeth Birk Møller
MTMette Bendixen Thorup
Mette Bendixen Thorup
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl
Background: Huppke–Brendel (HB) syndrome is an autosomal recessive disease caused by variants in the SLC33A1 gene. Since 2012, less than ten patients have been reported, none survived year six. With neurologic involvement and ceruloplasmin deficiency, it may mimic Wilson disease (WD).Objectives and methods: We report the first adult patient with HB.Results: The patient suffered from moderate intellectual disability, partial hearing loss, spastic ataxia, hypotonia, and unilateral tremor of parkinsonian type. At age 29, she was diagnosed with WD based on neurology, elevated 24H urinary copper, low ceruloplasmin, and pathological 65Cu test. Approximately 25 years later, genetic testing did not support WD or aceruloplasminemia. Full genome sequencing revealed two likely pathogenic variants in SLC33A1 which combined with re-evaluation of neurologic symptoms and MRI suggested the diagnosis of HB.Conclusion: Adult patients with HB exist and may be confused with WD. Low ceruloplasmin and the absence of ATP7B variants should raise suspicion.